ストックスクリーナーアプリを入手
28.31
1.91%
-0.55
前日終値:
$28.86
開ける：
$29.09
24時間の取引高:
1.33M
Relative Volume:
0.50
時価総額：
$1.54B
収益：
$27.10M
当期純損益:
$-24.31M
株価収益率:
-34.11
EPS:
-0.83
ネットキャッシュフロー:
$-33.33M
1週間 パフォーマンス:
-4.65%
1か月 パフォーマンス:
+345.13%
6か月 パフォーマンス:
+182.53%
1年 パフォーマンス:
+89.24%
1日の値動き範囲:
$27.51
$29.36
1週間の範囲:
$27.51
$30.71
52週間の値動き範囲:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
名前
Capricor Therapeutics Inc
セクター
電話
(310) 358-3200
住所
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
28.31 | 1.57B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | 開始されました | Alliance Global Partners | Buy |
| 2025-06-26 | 開始されました | B. Riley Securities | Buy |
| 2025-05-20 | 開始されました | Roth Capital | Buy |
| 2024-10-21 | 開始されました | Piper Sandler | Overweight |
| 2024-05-17 | 開始されました | Oppenheimer | Outperform |
| 2024-01-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-26 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-13 | 再開されました | Rodman & Renshaw | Buy |
| 2016-07-06 | 再開されました | H.C. Wainwright | Buy |
| 2016-06-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Capricor Therapeutics Inc (CAPR) 最新ニュース
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5%Here's What Happened - MarketBeat
HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Analyst Downgrade: How interest rate cuts could boost Capricor Therapeutics Inc stockWeekly Stock Analysis & Daily Profit Focused Stock Screening - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Trend Review: Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Buyback Activity & Safe Investment Capital Preservation Plans - moha.gov.vn
HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% - MarketBeat
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
Top Medical Stocks To ResearchDecember 3rd - MarketBeat
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal - Sahm
Capricor Therapeutics launches proposed public offering of common stock - MSN
Earnings Risk: Is ARK Autonomous Technology & Robotics stock cheap by valuation metricsMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Top Decliners & Low Risk High Win Rate Stock Picks - Улправда
How Capricor Therapeutics Inc. (4LN2) stock trades pre earningsQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Does Capricor Therapeutics Inc. stock trade at a discount to peers2025 Analyst Calls & Advanced Technical Signal Analysis - ulpravda.ru
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.8%What's Next? - MarketBeat
Capricor Therapeutics (STU:4LN2) EV-to-OCF : -21.03 (As of Dec. 19, 2025) - GuruFocus
Capricor Therapeutics (STU:4LN2) EV-to-FCF : -18.80 (As of Dec. 19, 2025) - GuruFocus
Can Capricor Therapeutics Inc. stock reach $100 price target2025 Pullback Review & Weekly Sector Rotation Insights - ulpravda.ru
Why Capricor Therapeutics Inc. (4LN2) stock is a strong analyst pick2025 Bull vs Bear & Low Drawdown Investment Ideas - DonanımHaber
CAPR stock price: Why is Capricor Therapeutics stock surging over 293% today? - MSN
Can Capricor Therapeutics Inc. (4LN2) stock double in coming years2025 Earnings Surprises & Detailed Earnings Play Alerts - Улправда
How Capricor Therapeutics Inc. stock reacts to global recession fears2025 Risk Factors & Weekly Stock Breakout Alerts - Улправда
How Capricor Therapeutics Inc. (4LN2) stock benefits from digital adoptionRecession Risk & Target Return Focused Stock Picks - Улправда
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory - Insider Monkey
Is Capricor Therapeutics Inc. stock attractive for long term wealth building2025 Price Targets & Smart Investment Allocation Tips - Улправда
Transcript : Capricor Therapeutics, Inc.Special Call - marketscreener.com
Piper Sandler reiterates Capricor stock rating, names it 2026 top pick - Investing.com UK
PPMD to host webinar on Capricor’s DMD therapy trial results By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Community Webinar on Positive HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy - The Manila Times
Capricor Therapeutics and Parent Project Muscular Dystrophy - GlobeNewswire
CAPR: B. Riley Securities Raises Target Price to $50, Maintains Buy Rating | CAPR Stock News - GuruFocus
B. Riley Adjusts Price Target on Capricor Therapeutics to $50 From $21, Maintains Buy Rating - marketscreener.com
Understanding the Setup: (CAPR) and Scalable Risk - news.stocktradersdaily.com
Capricor Therapeutics (CAPR): Reassessing Valuation After Positive Phase 3 HOPE-3 Results for Deramiocel - Sahm
How Investors May Respond To Capricor Therapeutics (CAPR) Phase 3 HOPE-3 Success And $150 Million Equity Raise - Sahm
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sidley Represents Capricor Therapeutics in US$172.5 Million Common Stock Offering - Sidley Austin
Capricor: A Detailed Examination Of Hope-3 (NASDAQ:CAPR) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on CAPR, Raises Price Target | CAPR Stock News - GuruFocus
What Does the Market Think About Capricor Therapeutics Inc? - Benzinga
Piper Sandler raises Capricor Therapeutics stock price target to $45 on trial success - Investing.com
Biotech Stocks To Add to Your WatchlistDecember 5th - MarketBeat
A strong week for data readouts: Clinical Report - BioCentury
Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial - Indian Pharma Post
Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Oppenheimer Maintains Capricor Therapeutics (CAPR) Outperform Recommendation - Nasdaq
Capricor Therapeutics Inc (CAPR) 財務データ
収益
当期純利益
現金流量
EPS
Capricor Therapeutics Inc (CAPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Marban Linda | CHIEF EXECUTIVE OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
223,604 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
0.57%
大文字化:
|
ボリューム (24 時間):